ClinicalTrials.gg
CompletedNCT03401502Updated Apr 10, 2019

A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency

An interventional study of Ranolazine and Placebos in Angina, sponsored by TSH Biopharm Corporation Limited. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-04-10.

Sponsored by TSH Biopharm Corporation Limited · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing ranolazine in Angina Pectoris — none open to participants now, none under way, none of them phase 3. Ranolazine · Angina Pectoris.

Enrollment
9th of 14
20 · median 44
Started
2018
the only one that year
No phase
Only one
of the 14
Registered
14th of 14
by date
Lead sponsor
1 of 14
TSH Biopharm Corporation Limited

Among the 14 studies testing ranolazine in Angina Pectoris, this one is the 9th largest by enrollment, is the only one that started in 2018, is the only one with no phase, and was the 14th registered.

Angina Pectoris

454 studies on the registry are indexed under Angina Pectoris; 68 are open to participants now.

Browse Angina Pectoris studies →

Open to participants now

None of the 14 studies testing ranolazine in Angina Pectoris is open now. The open studies under Angina Pectoris, anywhere →

About ranolazine

Ranolazine: first FDA approval 2006 (RANEXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Angina Pectoris studies recruiting now, 35 (74%) set no upper age limit and 1 (2%) stops at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing ranolazine in Angina Pectoris as a file.
02

Study summary

This is a double-blind, randomized, placebo-controlled, and parallel study. The study is comprised of three main phases: a single-blind placebo run-in qualifying phase lasting about 14 days, a double-blind treatment phase of 12 weeks, and a 2-week follow-up phase. Approximately 18 patients will be enrolled and randomly assigned to receive placebo or 1,000 mg of extended-release Ranolazine twice-daily for 12 weeks to reach 14 evaluable patients at the end of the study.

Read the detailed description

This is a double-blind, randomized, placebo-controlled, and parallel study. The study is comprised of three main phases: a single-blind placebo run-in qualifying phase lasting about 14 days, a double-blind treatment phase of 12 weeks, and a 2-week follow-up phase. Approximately 18 patients will be enrolled and randomly assigned to receive placebo or 1,000 mg of extended-release Ranolazine twice-daily for 12 weeks to reach 14 evaluable patients at the end of the study.

Patients with chronic angina pectoris will be screened for eligibility after providing informed consent. Patients present with the symptoms of stable angina after withdrawn from other antianginal agents and given the required background therapy for at least 5 days will be qualified for entering this study and performing 1st ETT qualifying test.

03

Conditions studied

  • Angina

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged ≥ 20 years old.
  2. A minimum 3-month history of stable angina.
  3. Patients with diagnosis of coronary artery disease (CAD) via at least one of the following criteria:

    • Angiographic evidence of ≥ 50% stenosis of ≥ 1 major coronary artery;
    • CT angiographic evidence of ≥ 50% stenosis of ≥ 1 major coronary artery;
    • History of previous myocardial infarction (MI)*;

      *Previous MI history of patients has to be occurred and diagnosed at least 2 months prior entering this study.

    • A stress-induced reversible perfusion defect identified by radionuclide or echocardiographic imaging.
  4. Patients present with the symptoms of stable angina after withdrawn from other antianginal drugs and given the required background therapy for at least 5 days will be qualified for entering this study and performing 1st ETT qualifying test.
  5. Patients developed exercise-induced ischemia during two qualifying exercise treadmill tests. The difference between twotests should be ≤ 20% of the longer test or ≤ 1 minute.
  6. Willing and able to provide a written .

Exclusion criteria

Exclusion Criteria:

  1. Factors that might compromise or ETT interpretation.

    • Patients with resting ST-segment depression ≥ 1mm in any lead.
    • Left bundle-branch block.
    • Patients implanted with pacemaker.
    • Patients under Digitalis therapy.
  2. Patients with family history of (or congenital) long syndrome.
  3. Patients with congenital heart disease.
  4. Patients with uncorrected valvular heart disease.
  5. Patients with unstable angina, or MI, or coronary revascularization procedure ≤ 2 months prior enter this study.
  6. Female who is pregnant/lactating or planning to be pregnant, or female of * who is not using medically recognized method of .

    *Other than those who have been surgically sterilized (defined as having undergone hysterectomy or bilateral oophorectomy or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year .

  7. Patients are under any one of the following conditions:

    • (NYHA) Class III or Class IV congestive heart failure (CHF);
    • QTc > 450 msec at screening;
    • Active myocarditis, pericarditis, hypertrophic cardiomyopathy;
    • Uncontrolled hypertension (defined as SBP > 180 mmHg). Voltage criteria for left ventricular hypertrophy in the absence of repolarization abnormalities will not be exclusion criteria.
  8. Use of any product ≤ 4 weeks prior to screening.
  9. Patients with severe hepatic disease (e.g., liver cirrhosis).
  10. Patients with impaired renal function (defined as serum Cr >1.5 mg/dl).
  11. Patients with any condition or disease which is considered not suitable for this study by investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment groups

    Ranolazine 1000 mg

    Drug: Ranolazine

  • Placebo comparator
    Control group

    Placebos

    Drug: Placebos

Interventions

  • Oral, b.i.d

    Also known as: RNTA

  • DrugPlacebos

    Oral, b.i.d

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. ETT performing duration

    To compare the change from baseline of ETT performing duration between add-on Ranolazine and placebo

    Time frame: at trough (12 hours after dosing) at Week 12

07

Study locations

1 site
  • National Taiwan University Hospital
    Taipei, Zhongzheng Dist 10048, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Mar 2019, 9 months.

Of 72 interventional studies with no phase under Angina Pectoris, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 64. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2018
First posted
Jan 17, 2018
StartActual
Jun 7, 2018
Primary completionActual
Mar 30, 2019
CompletionActual
Mar 31, 2019
Last update
Apr 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03401502
Lead sponsor
TSH Biopharm Corporation Limited
Responsible party
Sponsor
First posted
Jan 17, 2018
Start date
Jun 7, 2018
Primary completion
Mar 30, 2019
Completion
Mar 31, 2019
Last update
Apr 10, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion